Akira Arisawa
California Institute of Technology
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Akira Arisawa.
Chemistry & Biology | 1999
Hyun Joo; Akira Arisawa; Zhanglin Lin; Frances H. Arnold
BACKGROUND Oxygenases catalyze the hydroxylation of a wide variety of organic substrates. An ability to alter oxygenase substrate specificities and improve their activities and stabilities using recombinant DNA techniques would expand their use in processes such as chemical synthesis and bioremediation. Discovery and directed evolution of oxygenases require efficient screens that are sensitive to the activities of interest and can be applied to large numbers of crude enzyme samples. RESULTS Horseradish peroxidase (HRP) couples the phenolic products of hydroxylation of aromatic substrates to generate colored and/or fluorescent compounds that are easily detected spectroscopically in high-throughput screening. Coexpression of the coupling enzyme with a functional mono- or dioxygenase creates a pathway for the conversion of aromatic substrates into fluorescent compounds in vivo. We used this approach for detecting the products of the toluene-dioxygenase-catalyzed hydroxylation of chlorobenzene and to screen large mutant libraries of Pseudomonas putida cytochrome P450cam by fluorescence digital imaging. Colors generated by the HRP coupling reaction are sensitive to the site of oxygenase-catalyzed hydroxylation, allowing the screen to be used to identify catalysts with new or altered regiospecificities. CONCLUSIONS The coupled oxygenase-peroxidase reaction system is well suited for screening oxygenase libraries to identify mutants with desired features, including higher activity or stability and altered reaction specificity. This approach should also be useful for screening expressed DNA libraries and combinatorial chemical libraries for hydroxylation catalysts and for optimizing oxygenase reaction conditions.
Applied and Environmental Microbiology | 2001
Takeshi Sakamoto; John M. Joern; Akira Arisawa; Frances H. Arnold
ABSTRACT We are using directed evolution to extend the range of dioxygenase-catalyzed biotransformations to include substrates that are either poorly accepted or not accepted at all by the naturally occurring enzymes. Here we report on the oxidation of a heterocyclic substrate, 4-picoline, by toluene dioxygenase (TDO) and improvement of the enzymes activity by laboratory evolution. The biotransformation of 4-picoline proceeds at only ∼4.5% of the rate of the natural reaction on toluene. Random mutagenesis, saturation mutagenesis, and screening directly for product formation using a modified Gibbs assay generated mutant TDO 3-B38, in which the wild-type stop codon was replaced with a codon encoding threonine. Escherichia coli-expressed TDO 3-B38 exhibited 5.6 times higher activity toward 4-picoline and ∼20% more activity towards toluene than wild-type TDO. The product of the biotransformation of 4-picoline is 3-hydroxy-4-picoline; no cis-diols of 4-picoline were observed.
Journal of Biomolecular Screening | 2001
John M. Joern; Takeshi Sakamoto; Akira Arisawa; Frances H. Arnold
We have developed a solid-phase, high throughput (10,000 clones/day) screen for dioxygenase activity. The cis-di- hydrodiol product of dioxygenase bioconversion is converted to a phenol by acidification or to a catechol by reaction with cis-dihydrodiol dehydrogenase. Gibbs reagent reacts quickly with these oxygenated aromatics to yield colored products that are quantifiable using a microplate reader or by digital imaging and image analysis. The method is reproducible and quantitative at product concentrations of only 30,uM, with essentially no background from media components. This method is an effective general screen for aromatic oxidation and should be a useful tool for the discovery and directed evolution of oxygenases.
The Journal of Antibiotics | 2008
Hiroyuki Kumagai; Maya Umekita; Ryuichi Sawa; Yoshikazu Takahashi; Akira Arisawa; Kunio Isshiki; Yoshio Nishimura; Yuzuru Akamatsu
Benanomicins were found as antifungal antibiotics from the culture of an actinomycete with potent antifungal activities in vitro and in vivo. We aimed to generate derivatives superior to benanomicin A by biotransformation using Escherichia coli constructed with bacterial P450 expression system. We found transformation of benanomicin A into two derivatives, 10-hydroxybenanomicin A and 11-O-demethylbenanomicin A by one of the P450-expressed strains which harbored a plasmid carrying a CYP105C1-homologous gene. Unexpectedly, the biotransformed compounds showed weak antifungal activities in vitro compared with those of benanomicin A.
Applied and Environmental Microbiology | 2002
Akira Arisawa; Motoko Matsufuji; Takashi Nakashima; Kazuyuki Dobashi; Kunio Isshiki; Takeo Yoshioka; Shigeru Yamada; Haruo Momose; Seiichi Taguchi
ABSTRACT Streptomyces viridosporus A-914 was screened as a producer of an enzyme to effectively form chiral intermediates of 1,4-dihydropyridine calcium antagonists. The supernatant liquid of the growing culture of this strain exhibited high activity for enantioselective hydrolysis of prochiral 1,4-dihydropyridine diesters to the corresponding (4R) half esters. The responsible enzyme (termed DHP-A) was purified to apparent homogeneity and characterized. Cloning and sequence analysis of the gene for DHP-A (dhpA) revealed that the enzyme was a serine protease that is highly similar in both structural and enzymatic feature to SAM-P45, which is known as a target enzyme of Streptomyces subtilisin inhibitor (SSI), from Streptomyces albogriseolus. In a batch reaction test, DHP-A produced a higher yield of a chiral intermediate of 1,4-dihydropyridine than the commercially available protease P6. Homologous or heterologous expression of dhpA resulted in overproduction of the enzyme in culture supernatants, with 2.4- to 4.2-fold higher specific activities than in the parent S. viridosporus A-914. This indicates that DHP-A is suitable for use in reactions forming chiral intermediates of calcium antagonists and suggests the feasibility of developing DHP-A as a new commercial enzyme for use in the chiral drug industry.
Archive | 2002
Reiko Yamamoto; Masanori Yamaguchi; Hironori Kobayashi; Akira Arisawa; Kazuhiro Machida; Kunio Isshiki; Kenji Kanbe; Tsuyoshi Tamamura
Archive | 2008
Kazuhiro Machida; Shoji Ito; Yoshikazu Fujii; Shinji Hirosue; Akira Arisawa
Archive | 2011
Yoshiaki Yasutake; Yoshikazu Fujii; Taiki Nishioka; Woo-Kwang Cheon; Akira Arisawa; Tomohiro Tamura
Archive | 2009
Yoshikazu Fujii; 良和 藤井; Tadashi Fujii; 藤井 匡; Akira Arisawa; 有澤 章; Tomohiro Tamura; 田村 具博
Archive | 2009
Yoshikazu Fujii; 良和 藤井; Tadashi Fujii; 藤井 匡; Akira Arisawa; 有澤 章; Tomohiro Tamura; 田村 具博
Collaboration
Dive into the Akira Arisawa's collaboration.
National Institute of Advanced Industrial Science and Technology
View shared research outputs